

## Drug Formulary Committee

Sept. 17, 2025

Public Meeting – 9 a.m. to 1:30 p.m. (Central Time)

### **ALL MEMBERS OF THE GENERAL PUBLIC CAN ACCESS THE MEETING AS FOLLOWS:**

#### **Virtual option:**

Webinar Registration Link: [Minnesota Drug Formulary Committee Meeting Webinar Registration](#)

We recommend you register in advance to attend the webinar. After registering, you will receive a confirmation email containing information about joining the webinar.

The webinar will be open at 9 a.m. (Central Time) on Wednesday, Sept. 17, 2025.

#### **Directions for the public to sign up to provide live testimonials via webinar during the public forum:**

- Interested parties who wish to provide live testimonials during the public forum should email [mn.dhs.dfc@state.mn.us](mailto:mn.dhs.dfc@state.mn.us) no later than Wednesday, Sept. 17, 2025, 9 a.m. (Central Time) AND register for the webinar using the webinar registration link provided on this page before the date of the webinar.
- Interested parties must include a completed [Minnesota Drug Formulary Committee Meeting Public Comment Disclosure Form \(PDF\)](#) in their email request.
- Interested parties who sign up to provide live testimonials must check in to the webinar by 9:15 a.m. (Central Time) and be ready to provide their testimonials when their names are called. Their lines will be unmuted during the public forum. All other lines will be muted.
- An interested party's testimonial is limited to three minutes. If more than 20 people wish to provide public comment during the public forum, we will reduce the time to ensure all people are able to provide comment before the committee.

#### **In-person option:**

Elmer Andersen Building, Room 2370  
540 Cedar Street  
St. Paul, MN 55101

Note: All Drug Formulary Committee members will participate in the meeting virtually.

#### **Directions for the public to sign up to provide live testimonials in person during the public forum:**

- Interested parties who wish to provide live testimonials during the public forum should email [mn.dhs.dfc@state.mn.us](mailto:mn.dhs.dfc@state.mn.us) no later than Wednesday, Sept. 17, 2025, 9 a.m. (Central Time).

- Interested parties must include a completed [Minnesota Drug Formulary Committee Meeting Public Comment Disclosure Form \(PDF\)](#) in their email request.
- Interested parties who sign up to provide live testimonials in person must be present in room 2370 of Elmer Andersen Building at 9:15 a.m. (Central Time) and be ready to provide their testimonials when their names are called.
- An interested party's testimonial is limited to three minutes. If more than 20 people wish to provide public comment during the public forum, we will reduce the time to ensure all people are able to provide comment before the committee.

Email all questions regarding the Drug Formulary Committee meeting to: [mn.dhs.dfc@state.mn.us](mailto:mn.dhs.dfc@state.mn.us).

Check-In (in-person and virtual): 9 to 9:15 a.m. (Central Time)

Public Meeting: 9:15 a.m. to 1:30 p.m. (Central Time)

Find the meeting materials in the "Meeting materials" section on the [Drug Formulary Committee](#) webpage

1. Public Forum 9:15 a.m. up to 10:15 a.m. (Central Time)
2. Report of the Chair
3. Approval of the Minutes
4. DHS Housekeeping
5. Old Business:
6. New Business

## Select OTC drug coverage

---

Discussion Item:

1. OTC fat soluble vitamins

## Specialty Drugs for Continued PA

---

Discussion Items:

1. Niktimvo
2. Ctexli
3. Qfitlia
4. Vykat XR
5. Imaavy
6. Ryzneuta
7. Vanrafia

Consent Agenda Items:

1. Synagis
2. Botulinum toxins

## Preferred Drug List (PDL) Review

---

### Consent Agenda Items:

1. ANTIMIGRAINE AGENTS, OTHER
2. ANTIVIRALS, ORAL
3. ANTIVIRALS, TOPICAL
4. DIABETES METERS, CONTINUOUS
5. TRANSMITTERS AND SENSORS
6. HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIBITORS
7. IMMUNOMODULATORS, ASTHMA
8. LIPOTROPICS, STATINS
9. OPHTHALMIC ANTIBIOTICS
10. WEIGHT MANAGEMENT AGENTS

### Discussion Items:

1. ANDROGENIC AGENTS
2. GI MOTILITY, CHRONIC
3. GLUCAGON AGENTS
4. GLUCOCORTICOIDES, INHALED
5. GROWTH HORMONE
6. HYPOGLYCEMICS, INSULIN AND RELATED AGENTS
7. HYPOGLYCEMICS, SGLT2
8. HYPOGLYCEMICS, TZD
9. IMMUNOSUPPRESSIVES, ORAL
10. INTRANASAL RHINITIS AGENTS
11. LEUKOTRIENE MODIFIERS
12. MACROLIDES/KETOLIDES
13. NSAIDS
14. OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
15. OPHTHALMICS, ANTI-INFLAMMATORIES
16. OPHTHALMICS, DRY EYE AGENTS
17. OPHTHALMICS, GLAUCOMA AGENTS

## Adjourn

---